DPS Group expands U.S. headquarters at 959 Concord St. in Framingham, MA

Framingham, MA DPS Group, a privately-owned, global engineering, procurement, construction management and validation (EPCMV) firm serving high-tech process industries, has expanded its U.S. headquarters at 959 Concord St. to accommodate and serve the needs of its clients in an expanding market.

Founded in 1974 in Dublin, Ireland, to service the country’s burgeoning pharmaceutical sector, DPS Group opened its first office in the U.S. in 2011 with a staff of less than 10. The company has since grown its U.S. presence to over 900 employees across eight offices in Albany, NY; Cary, NC; Framingham, MA; Portland, OR; Kansas City, KS; Philadelphia, PA; Phoenix, AZ; and Wall Township, NJ.

The local office has designed three facilities for clients which have been named category winners of the prestigious Facility of the Year Award from the International Society of Pharmaceutical Engineering. The CRISPR Therapeutics manufacturing facility in Framingham was recognized as the category winner for innovation in 2022; ElevateBio’s BaseCamp, a cGMP development and manufacturing facility for novel therapeutic technologies, for operational excellence in 2021; and a new clinical development manufacturing facility for Moderna for facility of the future in 2019.

Additional recent projects include a new, 118,000 s/f late-phase clinical and commercial manufacturing facility at 1414 Massachusetts Ave. in Boxborough, Mass. for Vibalogics; and a 88,000 s/f facility for Oncorus on the Innovation Park campus located at 4 Corporate Dr. in Andover, Mass.